Second-hand smoke exposure in adulthood and lower respiratory health during 20 year follow up in the European Community Respiratory Health Survey.
Adult
Asthma
/ epidemiology
Bronchitis, Chronic
/ epidemiology
Dyspnea
/ epidemiology
Europe
/ epidemiology
European Union
Follow-Up Studies
Health Status
Health Surveys
Humans
Incidence
Prevalence
Respiratory Function Tests
Respiratory System
/ physiopathology
Respiratory Tract Diseases
/ epidemiology
Socioeconomic Factors
Tobacco Smoke Pollution
/ adverse effects
Adults
Asthma
Bronchitis
ECRHS
Lung function
Respiratory symptoms
Smoking
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
14 Feb 2019
14 Feb 2019
Historique:
received:
26
10
2018
accepted:
04
02
2019
entrez:
16
2
2019
pubmed:
16
2
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Early life exposure to tobacco smoke has been extensively studied but the role of second-hand smoke (SHS) for new-onset respiratory symptoms and lung function decline in adulthood has not been widely investigated in longitudinal studies. Our aim is to investigate the associations of exposure to SHS in adults with respiratory symptoms, respiratory conditions and lung function over 20 years. We used information from 3011 adults from 26 centres in 12 countries who participated in the European Community Respiratory Health Surveys I-III and were never or former smokers at all three surveys. Associations of SHS exposure with respiratory health (asthma symptom score, asthma, chronic bronchitis, COPD) were analysed using generalised linear mixed-effects models adjusted for confounding factors (including sex, age, smoking status, socioeconomic status and allergic sensitisation). Linear mixed-effects models with additional adjustment for height were used to assess the relationships between SHS exposure and lung function levels and decline. Reported exposure to SHS decreased in all 26 study centres over time. The prevalence of SHS exposure was 38.7% at baseline (1990-1994) and 7.1% after the 20-year follow-up (2008-2011). On average 2.4% of the study participants were not exposed at the first, but were exposed at the third examination. An increase in SHS exposure over time was associated with doctor-diagnosed asthma (odds ratio (OR): 2.7; 95% confidence interval (95%-CI): 1.2-5.9), chronic bronchitis (OR: 4.8; 95%-CI: 1.6-15.0), asthma symptom score (count ratio (CR): 1.9; 95%-CI: 1.2-2.9) and dyspnoea (OR: 2.7; 95%-CI: 1.1-6.7) compared to never exposed to SHS. Associations between increase in SHS exposure and incidence of COPD (OR: 2.0; 95%-CI: 0.6-6.0) or lung function (β: - 49 ml; 95%-CI: -132, 35 for FEV Exposure to second-hand smoke may lead to respiratory symptoms, but this is not accompanied by lung function changes.
Sections du résumé
BACKGROUND
BACKGROUND
Early life exposure to tobacco smoke has been extensively studied but the role of second-hand smoke (SHS) for new-onset respiratory symptoms and lung function decline in adulthood has not been widely investigated in longitudinal studies. Our aim is to investigate the associations of exposure to SHS in adults with respiratory symptoms, respiratory conditions and lung function over 20 years.
METHODS
METHODS
We used information from 3011 adults from 26 centres in 12 countries who participated in the European Community Respiratory Health Surveys I-III and were never or former smokers at all three surveys. Associations of SHS exposure with respiratory health (asthma symptom score, asthma, chronic bronchitis, COPD) were analysed using generalised linear mixed-effects models adjusted for confounding factors (including sex, age, smoking status, socioeconomic status and allergic sensitisation). Linear mixed-effects models with additional adjustment for height were used to assess the relationships between SHS exposure and lung function levels and decline.
RESULTS
RESULTS
Reported exposure to SHS decreased in all 26 study centres over time. The prevalence of SHS exposure was 38.7% at baseline (1990-1994) and 7.1% after the 20-year follow-up (2008-2011). On average 2.4% of the study participants were not exposed at the first, but were exposed at the third examination. An increase in SHS exposure over time was associated with doctor-diagnosed asthma (odds ratio (OR): 2.7; 95% confidence interval (95%-CI): 1.2-5.9), chronic bronchitis (OR: 4.8; 95%-CI: 1.6-15.0), asthma symptom score (count ratio (CR): 1.9; 95%-CI: 1.2-2.9) and dyspnoea (OR: 2.7; 95%-CI: 1.1-6.7) compared to never exposed to SHS. Associations between increase in SHS exposure and incidence of COPD (OR: 2.0; 95%-CI: 0.6-6.0) or lung function (β: - 49 ml; 95%-CI: -132, 35 for FEV
CONCLUSION
CONCLUSIONS
Exposure to second-hand smoke may lead to respiratory symptoms, but this is not accompanied by lung function changes.
Identifiants
pubmed: 30764884
doi: 10.1186/s12931-019-0996-z
pii: 10.1186/s12931-019-0996-z
pmc: PMC6376659
doi:
Substances chimiques
Tobacco Smoke Pollution
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901214
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L01341X/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : R01 MH062633
Pays : United States
Références
Thorax. 1999 Apr;54(4):357-66
pubmed: 10092699
Thorax. 1998 Oct;53(10):884-93
pubmed: 10193379
Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
pubmed: 11316667
Lancet. 2001 Dec 22-29;358(9299):2103-9
pubmed: 11784622
Environ Health Perspect. 2002 Aug;110(8):765-70
pubmed: 12153756
Eur Respir J. 2002 Nov;20(5):1071-9
pubmed: 12449157
Eur Respir J. 2003 Jun;21(6):1017-23
pubmed: 12797498
Am J Public Health. 2003 Dec;93(12):2055-60
pubmed: 14652334
Eur J Epidemiol. 2004;19(9):841-9
pubmed: 15499894
BMJ. 2005 Feb 5;330(7486):287-8
pubmed: 15677632
Environ Health. 2005 May 12;4(1):7
pubmed: 15890079
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Eur Respir J. 2006 Mar;27(3):517-24
pubmed: 16507851
Allergy. 2007 Feb;62(2):142-8
pubmed: 17298422
Int J Tuberc Lung Dis. 2007 May;11(5):502-7
pubmed: 17439672
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Lancet. 2007 Sep 1;370(9589):751-7
pubmed: 17765524
Thorax. 2010 Jan;65(1):14-20
pubmed: 19729360
BMC Public Health. 2010 Jan 28;10:44
pubmed: 20109222
Eur Respir J. 2010 Mar;35(3):676-80
pubmed: 20190332
Lancet. 2011 Jan 8;377(9760):139-46
pubmed: 21112082
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Thorax. 1990 Jan;45(1):27-31
pubmed: 2321173
Am J Respir Crit Care Med. 2013 Oct 1;188(7):776-82
pubmed: 23981189
Chest. 2014 Jun;145(6):1298-1304
pubmed: 24356778
Am J Respir Crit Care Med. 2015 Jan 15;191(2):168-76
pubmed: 25387276
JAMA Intern Med. 2015 Sep;175(9):1539-49
pubmed: 26098755
BMC Public Health. 2015 Dec 01;15:1202
pubmed: 26627181
N Engl J Med. 2016 May 12;374(19):1811-21
pubmed: 27168432
Lung. 2017 Feb;195(1):43-52
pubmed: 27738826
Physiol Rev. 2017 Apr;97(2):529-552
pubmed: 28151425
Am J Respir Crit Care Med. 2017 Oct 15;196(8):1021-1030
pubmed: 28530117
Thorax. 2018 Apr;73(4):376-384
pubmed: 29306902
Int J Epidemiol. 2018 Aug 1;47(4):1106-1117
pubmed: 29534228
Clin Chest Med. 1983 Sep;4(3):351-8
pubmed: 6357599
Eur Respir J. 1994 May;7(5):954-60
pubmed: 8050554
Thorax. 1998 Feb;53(2):117-23
pubmed: 9624297
Thorax. 1998 Mar;53(3):204-12
pubmed: 9659358